ID   ACY2_HUMAN              Reviewed;         313 AA.
AC   P45381;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Aspartoacylase;
DE            EC=3.5.1.15 {ECO:0000269|PubMed:24036223, ECO:0000269|PubMed:28101991};
DE   AltName: Full=Aminoacylase-2;
DE            Short=ACY-2;
GN   Name=ASPA; Synonyms=ACY2, ASP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT CAND ALA-285.
RC   TISSUE=Kidney;
RX   PubMed=8252036; DOI=10.1038/ng1093-118;
RA   Kaul R., Gao G.P., Balamurugan K., Matalon R.;
RT   "Cloning of the human aspartoacylase cDNA and a common missense
RT   mutation in Canavan disease.";
RL   Nat. Genet. 5:118-123(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   CHARACTERIZATION, CHARACTERIZATION OF VARIANT CAND ALA-285, AND
RP   MUTAGENESIS OF GLU-285.
RC   TISSUE=Brain;
RX   PubMed=12706335; DOI=10.1016/S0003-9861(03)00055-9;
RA   Moore R.A., Le Coq J., Faehnle C.R., Viola R.E.;
RT   "Purification and preliminary characterization of brain
RT   aspartoacylase.";
RL   Arch. Biochem. Biophys. 413:1-8(2003).
RN   [4]
RP   CATALYTIC ACTIVITY, ZINC-BINDING SITES, ACTIVE SITE, AND MUTAGENESIS
RP   OF GLU-178.
RX   PubMed=17027983; DOI=10.1016/j.febslet.2006.09.056;
RA   Herga S., Berrin J.G., Perrier J., Puigserver A., Giardina T.;
RT   "Identification of the zinc binding ligands and the catalytic residue
RT   in human aspartoacylase, an enzyme involved in Canavan disease.";
RL   FEBS Lett. 580:5899-5904(2006).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEXES WITH ZINC IONS;
RP   PHOSPHATE AND N-PHOSPHONOMETHYL-L-ASPARTATE, COFACTOR, SUBUNIT, AND
RP   MUTAGENESIS OF ARG-71; TYR-164; ARG-168; GLU-178 AND TYR-288.
RX   PubMed=18293939; DOI=10.1021/bi702400x;
RA   Le Coq J., Pavlovsky A., Malik R., Sanishvili R., Xu C., Viola R.E.;
RT   "Examination of the mechanism of human brain aspartoacylase through
RT   the binding of an intermediate analogue.";
RL   Biochemistry 47:3484-3492(2008).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS,
RP   SUBUNIT, AND COFACTOR.
RX   PubMed=17194761; DOI=10.1073/pnas.0607817104;
RA   Bitto E., Bingman C.A., Wesenberg G.E., McCoy J.G., Phillips G.N. Jr.;
RT   "Structure of aspartoacylase, the brain enzyme impaired in Canavan
RT   disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:456-461(2007).
RN   [7]
RP   VARIANTS CAND ALA-285 AND GLU-305.
RX   PubMed=8023850;
RA   Kaul R., Gao G.P., Aloya M., Balamurugan K., Petrosky A., Michals K.,
RA   Matalon R.;
RT   "Canavan disease: mutations among Jewish and non-Jewish patients.";
RL   Am. J. Hum. Genet. 55:34-41(1994).
RN   [8]
RP   VARIANTS CAND 176-GLY-ILE-177 DEL; ARG-274; SER-295 AND GLU-305.
RX   PubMed=7668285;
RA   Shaag A., Anikster Y., Christensen E., Glustein J.Z., Fois A.,
RA   Michelakakis H., Nigro F., Pronicka E., Ribes A., Zabot M.-T.,
RA   Elpeleg O.N.;
RT   "The molecular basis of canavan (aspartoacylase deficiency) disease in
RT   European non-Jewish patients.";
RL   Am. J. Hum. Genet. 57:572-580(1995).
RN   [9]
RP   VARIANT CAND ARG-152.
RX   PubMed=7599639; DOI=10.1002/humu.1380050313;
RA   Kaul R., Gao G.P., Michals K., Whelan D.T., Levin S., Matalon R.;
RT   "Novel (Cys152 > Arg) missense mutation in an Arab patient with
RT   Canavan disease.";
RL   Hum. Mutat. 5:269-271(1995).
RN   [10]
RP   VARIANTS CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152; CYS-168;
RP   ALA-285 AND GLU-305, VARIANT GLY-310, AND CHARACTERIZATION OF VARIANTS
RP   CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152 AND CYS-168.
RX   PubMed=8659549;
RA   Kaul R., Gao G.P., Matalon R., Aloya M., Su Q., Jin M., Johnson A.B.,
RA   Schutgens R.B.H., Clarke J.T.R.;
RT   "Identification and expression of eight novel mutations among non-
RT   Jewish patients with Canavan disease.";
RL   Am. J. Hum. Genet. 59:95-102(1996).
RN   [11]
RP   VARIANT CAND THR-143.
RX   PubMed=9452117;
RA   Kobayashi K., Tsujino S., Ezoe T., Hamaguchi H., Nihei K.,
RA   Sakuragawa N.;
RT   "Missense mutation (I143T) in a Japanese patient with Canavan
RT   disease.";
RL   Hum. Mutat. Suppl. 1:S308-S309(1998).
RN   [12]
RP   VARIANT CAND CYS-231.
RX   PubMed=10564886;
RX   DOI=10.1002/(SICI)1096-8628(19991126)87:3<273::AID-AJMG17>3.0.CO;2-O;
RA   Rady P.L., Vargas T., Tyring S.K., Matalon R., Langenbeck U.;
RT   "Novel missense mutation (Y231C) in a Turkish patient with Canavan
RT   disease.";
RL   Am. J. Med. Genet. 87:273-275(1999).
RN   [13]
RP   VARIANTS CAND THR-16; ARG-27; HIS-183; PHE-186; ARG-195; ARG-274;
RP   SER-280; LEU-280; THR-287; SER-295 AND GLU-305.
RX   PubMed=10407784; DOI=10.1023/A:1005512524957;
RA   Elpeleg O.N., Shaag A.;
RT   "The spectrum of mutations of the aspartoacylase gene in Canavan
RT   disease in non-Jewish patients.";
RL   J. Inherit. Metab. Dis. 22:531-534(1999).
RN   [14]
RP   VARIANTS CAND PRO-21; THR-57; HIS-168 AND THR-181.
RX   PubMed=10909858; DOI=10.1038/sj.ejhg.5200477;
RA   Sistermans E.A., de Coo R.F., van Beerendonk H.M., Poll-The B.T.,
RA   Kleijer W.J., van Oost B.A.;
RT   "Mutation detection in the aspartoacylase gene in 17 patients with
RT   Canavan disease: four new mutations in the non-Jewish population.";
RL   Eur. J. Hum. Genet. 8:557-560(2000).
RN   [15]
RP   VARIANTS CAND GLY-24; ALA-68; TRP-152; ARG-244 AND VAL-249.
RX   PubMed=12638939; DOI=10.1023/A:1022091223498;
RA   Zeng B.J., Wang Z.H., Ribeiro L.A., Leone P., De Gasperi R., Kim S.J.,
RA   Raghavan S., Ong E., Pastores G.M., Kolodny E.H.;
RT   "Identification and characterization of novel mutations of the
RT   aspartoacylase gene in non-Jewish patients with Canavan disease.";
RL   J. Inherit. Metab. Dis. 25:557-570(2002).
RN   [16]
RP   VARIANTS CAND TYR-114 AND VAL-249.
RX   PubMed=12205125; DOI=10.1136/jmg.39.9.e55;
RA   Olsen T.R., Tranebjaerg L., Kvittingen E.A., Hagenfeldt L., Moller C.,
RA   Nilssen O.;
RT   "Two novel aspartoacylase gene (ASPA) missense mutations specific to
RT   Norwegian and Swedish patients with Canavan disease.";
RL   J. Med. Genet. 39:E55-E55(2002).
RN   [17]
RP   VARIANT CAND THR-177, AND CATALYTIC ACTIVITY.
RX   PubMed=24036223; DOI=10.1016/j.clinbiochem.2013.09.004;
RA   Di Pietro V., Cavallari U., Amorini A.M., Lazzarino G., Longo S.,
RA   Poggiani C., Cavalli P., Tavazzi B.;
RT   "New T530C mutation in the aspartoacylase gene caused Canavan disease
RT   with no correlation between severity and N-acetylaspartate
RT   excretion.";
RL   Clin. Biochem. 46:1902-1904(2013).
RN   [18]
RP   VARIANTS CAND LYS-24; PRO-30; VAL-57; THR-63; ARG-69; VAL-101;
RP   LYS-129; THR-170; VAL-180; HIS-204; ARG-248 AND ASP-286,
RP   CHARACTERIZATION OF VARIANTS CAND LYS-24; PRO-30; VAL-57; THR-63;
RP   ARG-69; VAL-101; LYS-129; THR-170; VAL-180; HIS-204; ARG-248; ALA-285
RP   AND ASP-286, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=28101991; DOI=10.1002/humu.23181;
RA   Mendes M.I., Smith D.E., Pop A., Lennertz P., Fernandez Ojeda M.R.,
RA   Kanhai W.A., van Dooren S.J., Anikster Y., Baric I., Boelen C.,
RA   Campistol J., de Boer L., Kariminejad A., Kayserili H., Roubertie A.,
RA   Verbruggen K.T., Vianey-Saban C., Williams M., Salomons G.S.;
RT   "Clinically distinct phenotypes of Canavan disease correlate with
RT   residual aspartoacylase enzyme activity.";
RL   Hum. Mutat. 0:0-0(2017).
CC   -!- FUNCTION: Catalyzes the deacetylation of N-acetylaspartic acid
CC       (NAA) to produce acetate and L-aspartate. NAA occurs in high
CC       concentration in brain and its hydrolysis NAA plays a significant
CC       part in the maintenance of intact white matter. In other tissues
CC       it act as a scavenger of NAA from body fluids.
CC   -!- CATALYTIC ACTIVITY: N-acyl-L-aspartate + H(2)O = a carboxylate +
CC       L-aspartate. {ECO:0000269|PubMed:17027983,
CC       ECO:0000269|PubMed:24036223, ECO:0000269|PubMed:28101991}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:17194761,
CC         ECO:0000269|PubMed:18293939};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000269|PubMed:17194761,
CC       ECO:0000269|PubMed:18293939};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Vmax=1.2 nmol/h/mg enzyme {ECO:0000269|PubMed:28101991};
CC   -!- SUBUNIT: Homodimer. {ECO:0000305|PubMed:17194761,
CC       ECO:0000305|PubMed:18293939}.
CC   -!- INTERACTION:
CC       Q96HD9:ACY3; NbExp=9; IntAct=EBI-750475, EBI-3916242;
CC       Q68J44:DUPD1; NbExp=4; IntAct=EBI-750475, EBI-1054321;
CC       Q14145:KEAP1; NbExp=4; IntAct=EBI-750475, EBI-751001;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Brain white matter, skeletal muscle, kidney,
CC       adrenal glands, lung and liver.
CC   -!- DISEASE: Canavan disease (CAND) [MIM:271900]: A rare
CC       neurodegenerative condition of infancy or childhood characterized
CC       by white matter vacuolization and demyelination that gives rise to
CC       a spongy appearance. The clinical features are onset in early
CC       infancy, atonia of neck muscles, hypotonia, hyperextension of legs
CC       and flexion of arms, blindness, severe mental defect,
CC       megalocephaly, and death by 18 months on the average.
CC       {ECO:0000269|PubMed:10407784, ECO:0000269|PubMed:10564886,
CC       ECO:0000269|PubMed:10909858, ECO:0000269|PubMed:12205125,
CC       ECO:0000269|PubMed:12638939, ECO:0000269|PubMed:12706335,
CC       ECO:0000269|PubMed:24036223, ECO:0000269|PubMed:28101991,
CC       ECO:0000269|PubMed:7599639, ECO:0000269|PubMed:7668285,
CC       ECO:0000269|PubMed:8023850, ECO:0000269|PubMed:8252036,
CC       ECO:0000269|PubMed:8659549, ECO:0000269|PubMed:9452117}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the AspA/AstE family. Aspartoacylase
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S67156; AAB29190.1; -; mRNA.
DR   EMBL; BC029128; AAH29128.1; -; mRNA.
DR   CCDS; CCDS11028.1; -.
DR   PIR; S38538; S38538.
DR   RefSeq; NP_000040.1; NM_000049.2.
DR   RefSeq; NP_001121557.1; NM_001128085.1.
DR   RefSeq; XP_016880150.1; XM_017024661.1.
DR   UniGene; Hs.171142; -.
DR   PDB; 2I3C; X-ray; 2.80 A; A/B=2-313.
DR   PDB; 2O4H; X-ray; 2.70 A; A/B=1-313.
DR   PDB; 2O53; X-ray; 2.70 A; A/B=1-313.
DR   PDB; 2Q51; X-ray; 2.80 A; A/B=2-313.
DR   PDB; 4MRI; X-ray; 2.80 A; A/B=1-313.
DR   PDB; 4MXU; X-ray; 2.60 A; A/B=1-313.
DR   PDB; 4NFR; X-ray; 3.00 A; A/B=1-313.
DR   PDB; 4TNU; X-ray; 2.90 A; A/B=1-313.
DR   PDBsum; 2I3C; -.
DR   PDBsum; 2O4H; -.
DR   PDBsum; 2O53; -.
DR   PDBsum; 2Q51; -.
DR   PDBsum; 4MRI; -.
DR   PDBsum; 4MXU; -.
DR   PDBsum; 4NFR; -.
DR   PDBsum; 4TNU; -.
DR   ProteinModelPortal; P45381; -.
DR   SMR; P45381; -.
DR   BioGrid; 106935; 5.
DR   DIP; DIP-60793N; -.
DR   IntAct; P45381; 3.
DR   MINT; MINT-1440951; -.
DR   STRING; 9606.ENSP00000263080; -.
DR   DrugBank; DB00128; L-Aspartic Acid.
DR   iPTMnet; P45381; -.
DR   PhosphoSitePlus; P45381; -.
DR   BioMuta; ASPA; -.
DR   PaxDb; P45381; -.
DR   PeptideAtlas; P45381; -.
DR   PRIDE; P45381; -.
DR   DNASU; 443; -.
DR   Ensembl; ENST00000263080; ENSP00000263080; ENSG00000108381.
DR   Ensembl; ENST00000456349; ENSP00000409976; ENSG00000108381.
DR   GeneID; 443; -.
DR   KEGG; hsa:443; -.
DR   CTD; 443; -.
DR   DisGeNET; 443; -.
DR   GeneCards; ASPA; -.
DR   GeneReviews; ASPA; -.
DR   HGNC; HGNC:756; ASPA.
DR   HPA; HPA022142; -.
DR   HPA; HPA022145; -.
DR   MalaCards; ASPA; -.
DR   MIM; 271900; phenotype.
DR   MIM; 608034; gene.
DR   neXtProt; NX_P45381; -.
DR   OpenTargets; ENSG00000108381; -.
DR   Orphanet; 314918; Mild Canavan disease.
DR   Orphanet; 314911; Severe Canavan disease.
DR   PharmGKB; PA25055; -.
DR   eggNOG; ENOG410IERR; Eukaryota.
DR   eggNOG; COG2988; LUCA.
DR   GeneTree; ENSGT00390000001189; -.
DR   HOGENOM; HOG000232489; -.
DR   HOVERGEN; HBG004172; -.
DR   InParanoid; P45381; -.
DR   KO; K01437; -.
DR   OMA; NFNEGKE; -.
DR   OrthoDB; EOG091G0BL6; -.
DR   PhylomeDB; P45381; -.
DR   TreeFam; TF328708; -.
DR   BioCyc; MetaCyc:HS03094-MONOMER; -.
DR   BRENDA; 3.5.1.15; 2681.
DR   Reactome; R-HSA-70614; Amino acid synthesis and interconversion (transamination).
DR   EvolutionaryTrace; P45381; -.
DR   GenomeRNAi; 443; -.
DR   PRO; PR:P45381; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108381; -.
DR   CleanEx; HS_ASPA; -.
DR   ExpressionAtlas; P45381; baseline and differential.
DR   Genevisible; P45381; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0004046; F:aminoacylase activity; TAS:ProtInc.
DR   GO; GO:0019807; F:aspartoacylase activity; TAS:Reactome.
DR   GO; GO:0016788; F:hydrolase activity, acting on ester bonds; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006533; P:aspartate catabolic process; TAS:ProtInc.
DR   GO; GO:0008652; P:cellular amino acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0022010; P:central nervous system myelination; IEA:Ensembl.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   CDD; cd06909; M14_ASPA; 1.
DR   HAMAP; MF_00704; Aspartoacylase; 1.
DR   InterPro; IPR016708; Aspartoacylase.
DR   InterPro; IPR007036; Aste_AspA.
DR   Pfam; PF04952; AstE_AspA; 1.
DR   PIRSF; PIRSF018001; Aspartoacylase; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Disease mutation;
KW   Hydrolase; Leukodystrophy; Metal-binding; Nucleus; Reference proteome;
KW   Zinc.
FT   CHAIN         1    313       Aspartoacylase.
FT                                /FTId=PRO_0000216871.
FT   REGION       70     71       Substrate binding.
FT   REGION      164    168       Substrate binding.
FT   ACT_SITE    178    178       {ECO:0000269|PubMed:17027983}.
FT   METAL        21     21       Zinc.
FT   METAL        24     24       Zinc.
FT   METAL       116    116       Zinc.
FT   BINDING      63     63       Substrate.
FT   BINDING     178    178       Substrate.
FT   BINDING     288    288       Substrate.
FT   VARIANT      16     16       I -> T (in CAND; <0.5% residual enzyme
FT                                activity; dbSNP:rs769653717).
FT                                {ECO:0000269|PubMed:10407784,
FT                                ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039079.
FT   VARIANT      21     21       H -> P (in CAND).
FT                                {ECO:0000269|PubMed:10909858}.
FT                                /FTId=VAR_016778.
FT   VARIANT      24     24       E -> G (in CAND; dbSNP:rs104894551).
FT                                {ECO:0000269|PubMed:12638939}.
FT                                /FTId=VAR_016782.
FT   VARIANT      24     24       E -> K (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078086.
FT   VARIANT      27     27       G -> R (in CAND; 3% residual enzyme
FT                                activity; dbSNP:rs766328537).
FT                                {ECO:0000269|PubMed:10407784,
FT                                ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039080.
FT   VARIANT      30     30       L -> P (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078087.
FT   VARIANT      57     57       A -> T (in CAND).
FT                                {ECO:0000269|PubMed:10909858}.
FT                                /FTId=VAR_016779.
FT   VARIANT      57     57       A -> V (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078088.
FT   VARIANT      63     63       R -> T (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078089.
FT   VARIANT      68     68       D -> A (in CAND).
FT                                {ECO:0000269|PubMed:12638939}.
FT                                /FTId=VAR_016783.
FT   VARIANT      69     69       L -> R (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078090.
FT   VARIANT     101    101       G -> V (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078091.
FT   VARIANT     114    114       D -> E (in CAND; <0.5% residual enzyme
FT                                activity). {ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039081.
FT   VARIANT     114    114       D -> Y (in CAND).
FT                                {ECO:0000269|PubMed:12205125}.
FT                                /FTId=VAR_016784.
FT   VARIANT     123    123       G -> E (in CAND; about 25% residual
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039082.
FT   VARIANT     129    129       E -> K (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078092.
FT   VARIANT     143    143       I -> T (in CAND; dbSNP:rs777936704).
FT                                {ECO:0000269|PubMed:9452117}.
FT                                /FTId=VAR_004995.
FT   VARIANT     152    152       C -> R (in CAND; loss of activity;
FT                                dbSNP:rs104894548).
FT                                {ECO:0000269|PubMed:7599639}.
FT                                /FTId=VAR_004996.
FT   VARIANT     152    152       C -> W (in CAND).
FT                                {ECO:0000269|PubMed:12638939}.
FT                                /FTId=VAR_016785.
FT   VARIANT     152    152       C -> Y (in CAND; <0.5% residual enzyme
FT                                activity). {ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039083.
FT   VARIANT     168    168       R -> C (in CAND; undetectable enzyme
FT                                activity). {ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039084.
FT   VARIANT     168    168       R -> H (in CAND; dbSNP:rs770706390).
FT                                {ECO:0000269|PubMed:10909858}.
FT                                /FTId=VAR_016780.
FT   VARIANT     170    170       I -> T (in CAND; 5.5% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078093.
FT   VARIANT     176    177       Missing (in CAND).
FT                                {ECO:0000269|PubMed:7668285}.
FT                                /FTId=VAR_004997.
FT   VARIANT     177    177       I -> T (in CAND; Loss of catalytic
FT                                activity). {ECO:0000269|PubMed:24036223}.
FT                                /FTId=VAR_078094.
FT   VARIANT     180    180       G -> V (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078095.
FT   VARIANT     181    181       P -> T (in CAND; dbSNP:rs786204572).
FT                                {ECO:0000269|PubMed:10909858}.
FT                                /FTId=VAR_016781.
FT   VARIANT     183    183       P -> H (in CAND).
FT                                {ECO:0000269|PubMed:10407784}.
FT                                /FTId=VAR_039085.
FT   VARIANT     186    186       V -> F (in CAND).
FT                                {ECO:0000269|PubMed:10407784}.
FT                                /FTId=VAR_039086.
FT   VARIANT     195    195       M -> R (in CAND).
FT                                {ECO:0000269|PubMed:10407784}.
FT                                /FTId=VAR_039087.
FT   VARIANT     204    204       D -> H (in CAND; 12% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078096.
FT   VARIANT     231    231       Y -> C (in CAND; dbSNP:rs104894550).
FT                                {ECO:0000269|PubMed:10564886}.
FT                                /FTId=VAR_016786.
FT   VARIANT     244    244       H -> R (in CAND).
FT                                {ECO:0000269|PubMed:12638939}.
FT                                /FTId=VAR_016787.
FT   VARIANT     248    248       Q -> R (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078097.
FT   VARIANT     249    249       D -> V (in CAND; dbSNP:rs104894552).
FT                                {ECO:0000269|PubMed:12205125,
FT                                ECO:0000269|PubMed:12638939}.
FT                                /FTId=VAR_016788.
FT   VARIANT     274    274       G -> R (in CAND; dbSNP:rs761064915).
FT                                {ECO:0000269|PubMed:10407784,
FT                                ECO:0000269|PubMed:7668285}.
FT                                /FTId=VAR_004998.
FT   VARIANT     280    280       P -> L (in CAND).
FT                                {ECO:0000269|PubMed:10407784}.
FT                                /FTId=VAR_039088.
FT   VARIANT     280    280       P -> S (in CAND; dbSNP:rs750505963).
FT                                {ECO:0000269|PubMed:10407784}.
FT                                /FTId=VAR_039089.
FT   VARIANT     285    285       E -> A (in CAND; predominant mutation in
FT                                Ashkenazi Jewish population; 99% loss of
FT                                activity; dbSNP:rs28940279).
FT                                {ECO:0000269|PubMed:12706335,
FT                                ECO:0000269|PubMed:28101991,
FT                                ECO:0000269|PubMed:8023850,
FT                                ECO:0000269|PubMed:8252036,
FT                                ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_004999.
FT   VARIANT     286    286       A -> D (in CAND; <1% residual enzyme
FT                                activity). {ECO:0000269|PubMed:28101991}.
FT                                /FTId=VAR_078098.
FT   VARIANT     287    287       A -> T (in CAND; dbSNP:rs774323189).
FT                                {ECO:0000269|PubMed:10407784}.
FT                                /FTId=VAR_039090.
FT   VARIANT     295    295       F -> S (in CAND).
FT                                {ECO:0000269|PubMed:10407784,
FT                                ECO:0000269|PubMed:7668285}.
FT                                /FTId=VAR_005000.
FT   VARIANT     305    305       A -> E (in CAND; pan-European origin;
FT                                most prevalent among non-Jewish CAND
FT                                patients; probably the most ancient
FT                                mutation; loss of activity;
FT                                dbSNP:rs28940574).
FT                                {ECO:0000269|PubMed:10407784,
FT                                ECO:0000269|PubMed:7668285,
FT                                ECO:0000269|PubMed:8023850,
FT                                ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_005001.
FT   VARIANT     310    310       C -> G (in dbSNP:rs376854191).
FT                                {ECO:0000269|PubMed:8659549}.
FT                                /FTId=VAR_039091.
FT   MUTAGEN      71     71       R->K: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:18293939}.
FT   MUTAGEN     164    164       Y->F: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:18293939}.
FT   MUTAGEN     168    168       R->K: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:18293939}.
FT   MUTAGEN     178    178       E->A: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:17027983,
FT                                ECO:0000269|PubMed:18293939}.
FT   MUTAGEN     178    178       E->D: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:17027983,
FT                                ECO:0000269|PubMed:18293939}.
FT   MUTAGEN     178    178       E->Q: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:17027983,
FT                                ECO:0000269|PubMed:18293939}.
FT   MUTAGEN     285    285       E->D: 5-fold decrease in activity.
FT                                {ECO:0000269|PubMed:12706335}.
FT   MUTAGEN     288    288       Y->F: Reduces activity by 99%.
FT                                {ECO:0000269|PubMed:18293939}.
FT   STRAND       14     18       {ECO:0000244|PDB:4MXU}.
FT   HELIX        25     34       {ECO:0000244|PDB:4MXU}.
FT   HELIX        39     41       {ECO:0000244|PDB:4MXU}.
FT   STRAND       48     53       {ECO:0000244|PDB:4MXU}.
FT   HELIX        55     59       {ECO:0000244|PDB:4MXU}.
FT   STRAND       65     67       {ECO:0000244|PDB:4MXU}.
FT   HELIX        69     71       {ECO:0000244|PDB:4MXU}.
FT   HELIX        75     78       {ECO:0000244|PDB:4MXU}.
FT   STRAND       84     86       {ECO:0000244|PDB:4TNU}.
FT   HELIX        88    100       {ECO:0000244|PDB:4MXU}.
FT   STRAND      105    108       {ECO:0000244|PDB:2O4H}.
FT   STRAND      110    117       {ECO:0000244|PDB:4MXU}.
FT   STRAND      119    121       {ECO:0000244|PDB:4MXU}.
FT   STRAND      123    129       {ECO:0000244|PDB:4MXU}.
FT   HELIX       134    147       {ECO:0000244|PDB:4MXU}.
FT   STRAND      152    156       {ECO:0000244|PDB:4MXU}.
FT   STRAND      160    162       {ECO:0000244|PDB:2O4H}.
FT   HELIX       167    170       {ECO:0000244|PDB:4MXU}.
FT   STRAND      171    181       {ECO:0000244|PDB:4MXU}.
FT   HELIX       189    210       {ECO:0000244|PDB:4MXU}.
FT   STRAND      218    229       {ECO:0000244|PDB:4MXU}.
FT   STRAND      237    239       {ECO:0000244|PDB:4MXU}.
FT   STRAND      241    243       {ECO:0000244|PDB:2O53}.
FT   TURN        245    249       {ECO:0000244|PDB:4MXU}.
FT   STRAND      259    263       {ECO:0000244|PDB:4MXU}.
FT   STRAND      269    271       {ECO:0000244|PDB:4MXU}.
FT   STRAND      274    276       {ECO:0000244|PDB:4MXU}.
FT   STRAND      278    282       {ECO:0000244|PDB:4MXU}.
FT   HELIX       286    288       {ECO:0000244|PDB:4MXU}.
FT   TURN        289    292       {ECO:0000244|PDB:4MXU}.
FT   STRAND      294    305       {ECO:0000244|PDB:4MXU}.
SQ   SEQUENCE   313 AA;  35735 MW;  33C0B9B07839E7F5 CRC64;
     MTSCHIAEEH IQKVAIFGGT HGNELTGVFL VKHWLENGAE IQRTGLEVKP FITNPRAVKK
     CTRYIDCDLN RIFDLENLGK KMSEDLPYEV RRAQEINHLF GPKDSEDSYD IIFDLHNTTS
     NMGCTLILED SRNNFLIQMF HYIKTSLAPL PCYVYLIEHP SLKYATTRSI AKYPVGIEVG
     PQPQGVLRAD ILDQMRKMIK HALDFIHHFN EGKEFPPCAI EVYKIIEKVD YPRDENGEIA
     AIIHPNLQDQ DWKPLHPGDP MFLTLDGKTI PLGGDCTVYP VFVNEAAYYE KKEAFAKTTK
     LTLNAKSIRC CLH
//
